DekaBank Deutsche Girozentrale Raises Stock Position in CVS Health Corporation (NYSE:CVS)

DekaBank Deutsche Girozentrale raised its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 2.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,901,908 shares of the pharmacy operator's stock after buying an additional 43,352 shares during the period. DekaBank Deutsche Girozentrale owned about 0.15% of CVS Health worth $126,847,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Personal CFO Solutions LLC lifted its position in shares of CVS Health by 11.1% during the first quarter. Personal CFO Solutions LLC now owns 11,136 shares of the pharmacy operator's stock valued at $754,000 after purchasing an additional 1,116 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in shares of CVS Health by 5.3% in the first quarter. Valeo Financial Advisors LLC now owns 30,489 shares of the pharmacy operator's stock worth $2,066,000 after purchasing an additional 1,532 shares in the last quarter. CapWealth Advisors LLC increased its stake in shares of CVS Health by 7.1% in the first quarter. CapWealth Advisors LLC now owns 361,854 shares of the pharmacy operator's stock worth $24,516,000 after purchasing an additional 23,877 shares in the last quarter. Bank Hapoalim BM purchased a new position in shares of CVS Health in the first quarter worth about $269,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of CVS Health in the first quarter worth about $2,566,000. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Down 1.6%

Shares of CVS traded down $1.08 during mid-day trading on Thursday, reaching $65.58. The company's stock had a trading volume of 6,269,250 shares, compared to its average volume of 10,799,028. The stock has a market cap of $82.96 billion, a PE ratio of 15.65, a P/E/G ratio of 0.96 and a beta of 0.57. The company has a current ratio of 0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51. The company's fifty day moving average price is $65.18 and its two-hundred day moving average price is $61.93.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The firm had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. During the same period in the previous year, the business posted $1.31 EPS. The business's quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Tuesday, July 22nd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.06%. The ex-dividend date of this dividend is Tuesday, July 22nd. CVS Health's payout ratio is 63.48%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on CVS shares. Jefferies Financial Group raised their price objective on shares of CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Mizuho raised their price objective on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Barclays set a $79.00 price objective on shares of CVS Health and gave the company an "overweight" rating in a research report on Monday, June 2nd. Cowen restated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Finally, Royal Bank Of Canada raised their price objective on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research report on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $75.06.

Insider Activity at CVS Health

In related news, Director Guy P. Sansone acquired 1,570 shares of CVS Health stock in a transaction on Thursday, June 5th. The shares were acquired at an average cost of $63.70 per share, with a total value of $100,009.00. Following the transaction, the director owned 12,007 shares in the company, valued at $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.22% of the stock is currently owned by insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.